Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q4 earnings results on Thursday, March 6th, after market close. The consensus EPS Estimate is -$0.12 (+40.0% Y/Y) and the consensus ...
Fintel on MSN21h
Leerink Partners Downgrades Lexicon Pharmaceuticals (LXRX)Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback